If you follow psychedelic medicine at all, this was a big week. We keep an eye on Tricycle Day, a newsletter that tracks psychedelic research, policy, and business, and their July 15 issue captured something hard to ignore: on a single Monday, five different federal agencies dropped psychedelics-related news within hours of one another. When Washington moves that much in one direction, it is worth paying attention — especially here in Indiana, where thousands of veterans and patients with treatment-resistant conditions are still waiting for better options.
Here is what happened, why it matters, and [just as important] what it does not change for patients today 🥴
The federal government just got serious about psychedelic medicine
The headline development is a coordinated push across agencies that usually move on their own timelines. A few pieces stood out:
- The FDA released final guidance on how to design clinical trials for psychedelic drugs and scheduled a public hearing on the future of these therapies. Clear rules of the road are what turn promising research into treatments that can actually reach patients.
- HHS and the VA signed a five-year agreement to coordinate research, train clinicians, and prepare to roll out approved psychedelic treatments for veterans. A second memo has the FDA and VA sharing trial data directly.
- NIDA revived older ibogaine research and funded a new $11 million project at Harvard to bring the compound through its first U.S. clinical trials, while ARPA-H opened funding specifically for ibogaine research targeting opioid use disorder.
- HRSA asked for public input on how community health centers and clinicians should prepare for these drugs if and when they are approved.
As Tricycle Day put it, you do not build this much infrastructure unless you plan to use it. None of it changes what a patient can walk in and receive tomorrow — but it is the clearest signal yet that psychedelic-assisted therapy is being taken seriously at the highest levels. Yay…
Why the veterans angle hits home in Indiana
The HHS–VA agreement is the part we keep coming back to. Indiana is home to more than 350,000 veterans, and many carry the kind of treatment-resistant depression, PTSD, and chronic pain that conventional care too often fails to reach. A federal commitment to study and eventually deliver psychedelic therapies through the VA could, in time, matter enormously for Hoosier families.
The key phrase, though, is “in time.” Psilocybin, MDMA, and ibogaine remain investigational in the United States. They are moving through trials, not clinics. For the veteran or the patient who is struggling right now, the honest answer is that these particular options are not yet available outside a research setting.
What patients can actually access today
This is where ketamine comes in. Among the therapies in the broader psychedelic conversation, ketamine is the one that is legal, established, and available now under medical supervision. It has decades of use in medicine, and low-dose IV infusions have become a recognized option for treatment-resistant depression, anxiety, PTSD, and certain chronic pain conditions the very conditions the federal push is aimed at.
In other words, while the country builds the runway for future psychedelic treatments, ketamine therapy is already here. That is what we do at AlphaOmega Wellness in Greenwood, serving patients across Central Indiana who have often already tried conventional treatments without enough relief.
A timely reminder about safety
Tucked into the same week’s news was a smaller but important item: the FDA is cracking down on illicit online ketamine sellers. It is a useful reminder that the same molecule can be delivered responsibly or recklessly, and the difference is everything. Ketamine belongs in a screened, monitored, physician-led setting… not a mailbox. 😅😬
At AlphaOmega, our medical director, Dr. Dee Bonney, MD, a board-certified emergency physician, oversees all infusion care, and either Dr. Bonney or an ACLS-certified medic is present in the clinic during every infusion + provider. As federal attention brings more people to this conversation, that kind of oversight is exactly what separates real treatment from a shortcut.
Also worth watching
A couple of other items from the week point in the same encouraging direction. Massachusetts lawmakers advanced a five-year psychedelic therapy pilot that would let a small number of licensed mental health clinics administer natural psychedelics under strict supervision — notably barring cannabis and pharmaceutical companies from running them, and creating a fund to keep treatment accessible to low-income patients. And a new pilot study out of Imperial College London found that psilocybin therapy helped adult women with anorexia nervosa, a condition with the highest mortality rate in psychiatry and remarkably few effective treatments. Both are early, but both suggest the evidence base keeps widening.
The bottom line
The federal government spent this week laying groundwork for a future where psychedelic medicine is part of mainstream care. That future is not here yet — but the direction is unmistakable, and for veterans and patients with hard-to-treat conditions, it is genuinely hopeful (AND DEFINITELY SOMETHING TO CELEBRATE). In the meantime, ketamine remains the option you can pursue today, safely and legally, with a physician overseeing your care.
We recap developments like these because staying informed helps patients make good decisions. If you want the same weekly rundown we read, we recommend subscribing to Tricycle Day. And if you are in Central Indiana and wondering whether ketamine therapy might be right for you, our team at AlphaOmega Wellness is here to talk it through. Book your ketamine call now.
This article is for general educational purposes and is not medical advice. Psilocybin, MDMA, and ibogaine are investigational and not approved for general clinical use. Please consult a qualified provider about your individual situation.